Trial · NCT02239120
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Adjudicated Recurrent Stroke | Dabigatran Etexilate 110 or 150 Milligram (mg) | 4.09 | Annualised event rate (%/ year) | ||
| Adjudicated Recurrent Stroke | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 4.80 | Annualised event rate (%/ year) | ||
| First Major Bleed (Adjudicated) | Dabigatran Etexilate 110 or 150 Milligram (mg) | 1.84 | Annualised event rate (%/ year) | ||
| First Major Bleed (Adjudicated) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 1.33 | Annualised event rate (%/ year) | ||
| Adjudicated Ischaemic Stroke | Dabigatran Etexilate 110 or 150 Milligram (mg) | 3.97 | Annualised event rate (%/ year) | ||
| Adjudicated Ischaemic Stroke | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 4.71 | Annualised event rate (%/ year) | ||
| Adjudicated Composite of Non-fatal Stroke, Non-fatal Myocardial Infarction, or Cardiovascular Death | Dabigatran Etexilate 110 or 150 Milligram (mg) | 4.80 | Annualised event rate (%/ year) | ||
| Adjudicated Composite of Non-fatal Stroke, Non-fatal Myocardial Infarction, or Cardiovascular Death | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 5.40 | Annualised event rate (%/ year) | ||
| Disabling Stroke | Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.55 | Annualised event rate (%/ year) | ||
| Disabling Stroke | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.93 | Annualised event rate (%/ year) | ||
| All-cause Death | Dabigatran Etexilate 110 or 150 Milligram (mg) | 1.24 | Annualised event rate (%/ year) | ||
| All-cause Death | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 1.28 | Annualised event rate (%/ year) | ||
| Adjudicated Intracranial Hemorrhage | Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.67 | Annualised event rate (%/ year) | ||
| Adjudicated Intracranial Hemorrhage | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.63 | Annualised event rate (%/ year) | ||
| Adjudicated Fatal Bleed | Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.00 | Annualised event rate (%/ year) | ||
| Adjudicated Fatal Bleed | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.05 | Annualised event rate (%/ year) | ||
| Adjudicated Life-threatening Bleed | Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.76 | Annualised event rate (%/ year) | ||
| Adjudicated Life-threatening Bleed | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.91 | Annualised event rate (%/ year) | ||
| Any Bleed (Investigator-reported) | Dabigatran Etexilate 110 or 150 Milligram (mg) | 15.21 | Annualised event rate (%/ year) | ||
| Any Bleed (Investigator-reported) | Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 11.64 | Annualised event rate (%/ year) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02239120/results